Anja Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Affordable cord blood and tissue banking with FDA-registered storage for broader stem cell access; $4.62M from Seven Seven Six and YC at $1.8M revenue competing with CBR for expectant parent insurance market.
About
Anja Health is a San Jose-based cord blood and cord tissue banking company that makes stem cell preservation from newborn births accessible and affordable — providing nationwide FDA-registered collection and storage of umbilical cord blood and cord tissue that contain hematopoietic stem cells and mesenchymal stem cells, which may be used in future treatments for blood disorders, immune conditions, and emerging regenerative medicine applications. Founded in 2021 and backed by Alexis Ohanian's Seven Seven Six fund and Y Combinator with $4.62 million raised including a $2 million seed round in May 2024, Anja Health achieved $1.8 million in revenue as of December 2024.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.